Generic name: micafungin sodium
Dosage form: injection, powder, lyophilized, for solution
This dosage information does not include all the information needed to use Mycamine safely and effectively. See full prescribing information for Mycamine.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Do not mix or co-infuse Mycamine with other medications. Mycamine has been shown to precipitate when mixed directly with a number of other commonly used medications.
Recommended Reconstituted Dose Once Daily
|Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses*||100 mg|
|Treatment of Esophageal Candidiasis†||150 mg|
|Prophylaxis of Candida Infections in HSCT Recipients‡||50 mg|
A loading dose is not required. Typically, 85% of the steady-state concentration is achieved after three daily Mycamine doses.
No dosing adjustments are required based on race, gender, or in patients with severe renal impairment or in patients with mild, moderate, or severe hepatic impairment [see Use in Specific Populations (8)].
No dose adjustment for Mycamine is required with concomitant use of mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, voriconazole, itraconazole, amphotericin B, ritonavir, or rifampin [see Drug Interactions (7)].
Directions for Reconstitution and Dilution
Please read this entire section carefully before beginning reconstitution.
The diluent to be used for reconstitution and dilution is 0.9% Sodium Chloride Injection, USP (without a bacteriostatic agent). Alternatively, 5% Dextrose Injection, USP, may be used for reconstitution and dilution of Mycamine. Solutions for infusion are prepared as follows:
Mycamine 50 mg vial
Aseptically add 5 mL of 0.9% Sodium Chloride Injection, USP (without a bacteriostatic agent) to each 50 mg vial to yield a preparation containing approximately 10 mg micafungin/mL.
Mycamine 100 mg vial
Aseptically add 5 mL of 0.9% Sodium Chloride Injection, USP (without a bacteriostatic agent) to each 100 mg vial to yield a preparation containing approximately 20 mg micafungin/mL.
As with all parenteral drug products, reconstituted Mycamine should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use material if there is any evidence of precipitation or foreign matter. Aseptic technique must be strictly observed in all handling since no preservative or bacteriostatic agent is present in Mycamine or in the materials specified for reconstitution and dilution.
To minimize excessive foaming, GENTLY dissolve the Mycamine powder by swirling the vial. DO NOT VIGOROUSLY SHAKE THE VIAL. Visually inspect the vial for particulate matter.
The diluted solution should be protected from light. It is not necessary to cover the infusion drip chamber or the tubing.
- For treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses: add 100 mg of reconstituted Mycamine [see Dosage and Administration (2.1)] into 100 mL of 0.9% Sodium Chloride Injection, USP or 100 mL of 5% Dextrose Injection, USP.
- For treatment of esophageal candidiasis: add 150 mg of reconstituted Mycamine [see Dosage and Administration (2.1)] into 100 mL of 0.9% Sodium Chloride Injection, USP or 100 mL of 5% Dextrose Injection, USP.
- For prophylaxis of Candida infections: add 50 mg of reconstituted Mycamine [see Dosage and Administration (2.1)] into 100 mL of 0.9% Sodium Chloride Injection, USP or 100 mL of 5% Dextrose Injection, USP.
Mycamine is preservative-free. Discard partially used vials.
Infusion Volume and Duration
Mycamine should be administered by intravenous infusion only. Infuse over one hour. More rapid infusions may result in more frequent histamine mediated reactions.
An existing intravenous line should be flushed with 0.9% Sodium Chloride Injection, USP, prior to infusion of Mycamine.